Team – Oxford Science Enterprises

Will joined Oxford Science Enterprises as a founding Principal in 2015. He has previously worked for the China Britain Business Council in Beijing, E.L.I. Holdings in Chengdu, Text Publishing in Melbourne and as a Publishing Director at Penguin UK. He holds a BA in Philosophy, Politics and Economics from the University of Oxford and an MSc in Economic History from the London School of Economics. Will is responsible for investments in Alloyed, Animal Dynamics, Brill Power, First Light Fusion, Metaboards, Odqa Renewable Energy Technologies, Orca Computing, Oxford Quantum Circuits, Oxford Ionics, Quantum Motion, Util and YASA. He is a Trustee of Nekton, a marine research foundation.

William Goodlad

Principal, Deep Tech

Team

Athene joined Oxford Science Enterprises as Head of Legal in January 2022. Prior to this, she was Managing Director of Benchmark Holdings plc’s Advanced Nutrition division from 2019 to 2021, and Group Legal Counsel of Benchmark Holdings plc from 2014 to 2019. Athene also served as a NED of the Great Salt Lake Brine Shrimp Cooperative in Utah, USA. She has transactional, public company, and international business experience both as a lawyer and as a business leader. Athene trained and qualified as a solicitor at Slaughter and May, and spent 9 years in the Corporate Finance teams both there and at Travers Smith. She holds a BA in Jurisprudence from St John’s College, Oxford.

Athene Blakeman

Head of Legal

Team

Polly joined Oxford Science Enterprises as Head of Investor relations & Co-investing in September 2020. She has over fifteen years’ experience in public equity markets, working across research and equity sales roles for a number of investment banks. The majority of her career was spent at UBS, where she joined as a media analyst during the TMT boom and moved on to lead Telecom and Media equity specialist sales. At UBS she built strong relationships with key equity investors and led the sales effort on a number of prominent IPOs. More recently, Polly has worked with public companies to help sharpen their investor messaging and strengthen their shareholder bases. For the past five years, she has led Investor Relations and Corporate PR at FTSE 250 group Electrocomponents, during a period of leadership change and significant transformation for both the equity story and shareholder base.

Polly Elvin

Head of Investor Relations & Co-Investors

Team

Sir John Bell has represented the University on the Board of Oxford Science Enterprises since its foundation. He is the Regius Professor of Medicine at the University of Oxford. He was the founder of the Wellcome Trust Centre for Human Genetics and has played a key role in the expansion of biomedical research at the University. He now leads the development of the Medical SciencesDivision’s research strategies and plays a major role in external relations. Sir John Bell was a NED at Roche AG between 2001 and 2020 and was a NED on the Genentech Board between 2010 and 2020. He is Chairman of the Bill & Melinda Gates Foundation Global Health Advisory Board. He sits on the board of Genomics England and chairs its Science Advisory Committee.He was President of The Academy of Medical Sciences from 2006 to 2011 and is a founding Director of three biotech start-ups. He is currently Chair of Immunocore a NASDAQ listed immuno-oncology company based in Oxford. Sir John Bell trained in Medicine at the University of Oxford and at Stanford and his scientific expertise is in Immunology and Genetics. He has been the Governement’s Life Sciences Champion under three administrations since 2011, leading the country’s Life Science Strategy. He is a Rhodes scholar and currently Chairs The Rhodes Trust.

Sir John Bell

Non-Executive Director

Board

Vishal joined Oxford Science Enterprises as an advisor in October 2019. He has experience in investment at the intersection of life sciences and engineering. He is an investor at Draper Esprit, where he has led investments in some of Europe’s leading digital healthcare companies, including Clue, PushDR, Lifesum and Evonetix. He is also a Director at Horizon Discovery and Sensyne Health. Vishal is Chairman of the Digital Health Forum and serves on Innovate UK’s Major Award committee. Vishal has previously worked at Atlas Venture, The Wellcome Trust and Radiant Capital. He trained in Medicine at the University of Oxford and received his postgraduate medical training at Imperial College London. He is a Rhodes scholar.

Vishal Gulati

Advisor

Team

Oliver joined Oxford Science Enterprises as an Investment Manager in November 2021. Prior to joining, he was at Concept Dairy, a fintech start-up bringing transparency to the dairy markets and fair milk prices to farmers. He worked at Scott Investment Partners, investing in medium and large cap global equity public markets. Oliver also a PhD in Regenerative Medicine from Imperial College London, where he investigated strategies for bone regeneration. As well as this Oliver has a MEng in Mechanical Engineering, also from Imperial College London.

Oliver Mahony

Investment Manager

Team

Lisa joined Oxford Science Enterprises as Senior Communications Manager in September 2020. Prior to this she was Communications Manager for Medicines Discovery Catapult, responsible for translating complex science into simple but compelling stories, championing innovative technologies and new approaches to reshape drug discovery. Lisa has nearly 10 years’ experience working within the pharmaceutical and biotechnology industries. This includes supporting US-based start-up biotechs, entrepreneurs and innovators to define their offering; producing professional and creative communications to attract investment. Lisa holds a BSc in Psychology and an MSc focused on Developmental Cognitive Neuroscience from Durham University. Here, Lisa tells our story – promoting our enterprises, the ground-breaking technologies, people and companies that create them.

Lisa Bedwell

Head of Marketing

Team

Chris joined Oxford Science Enterprises in December 2019. He is a seasoned biotech entrepreneur with over 35 years’ experience in the biotechnology industry. Chris has considerable expertise in leading and growing early stage companies and their transition to mid-stage clinical development organisations. He has extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity. Chris was formerly a Partner at Syncona, a FTSE250 company, where he was also founding CEO of Achilles Therapeutics. Prior to that he was CEO of Argenta Discovery (sold to Galapagos) and Pulmagen Therapeutics. Chris has a PhD from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).

Chris Ashton

Advisor

Team

Wallace joined Oxford Science Enterprises as an Associate within the Life Sciences team in March 2022. She supports the creation of new businesses and ongoing work across the portfolio. She was previously an associate at M-Ventures, the corporate venture capital arm of Merck KGaA, where she supported the life sciences investment team. Prior to this, Wallace worked at Accenture as a consultant, assisting the Business Strategy and Operation Strategy units, advising financial services clients. She holds a BSc in Genetics from the University of York and an MPhil in Bioscience Enterprise from the University of Cambridge.

Wallace Wallace

Associate, Life Sciences

Team

Ceri joined Oxford Science Enterprises as Head of Late-Stage Portfolio in August 2021. She joins the team after 20 years on the public sell side. Ceri began her career as a Life Science / Healthcare analyst at Beeson Gregory, moving into Specialist Sales roles at Peel Hunt and most recently Numis Securities. Both achieved #1 rankings by corporates and fund managers during her tenure. Ceri has been extensively involved in both primary and secondary fund raisings for the UK healthcare and life science sectors and is passionate about supporting the commercialisation of UK assets and their role in securing the UK as the globally leading centre for innovation. Ceri has an MB ChB from University of Birmingham Medical School, and post-graduation specialised in cardiology and trauma medicine.

Ceri Morgan

Head of Late Stage Portfolio

Team

Rawan joined Oxford Science Enterprises as an Associate in the Deep Tech team in October 2021. Her responsibilities range from deal origination, structuring, execution, through to managing portfolio companies and she represents Oxford Science Enterprises on the boards of Util and ORCA Computing. Prior to Oxford Science Enterprises, Rawan was a Vice President at Goldman Sachs leading the automation efforts in financial reporting. Rawan has a Master of Finance from the Judge Business School, University of Cambridge, and a BSc in Computer Science from UCL.

Rawan Farwana

Associate, Deep Tech

Team

Claire joined Oxford Science Enterprises in September 2020 as a Life Sciences Investment Principal and is on secondment from Biocity, a Life Science incubator network. At Biocity, Claire is an Investment Director and was responsible for the deployment of the Alderley Park Venture Fund, a seed fund developed with AstraZeneca. She has had a varied career across the BioPharmaceutical industry from R&D strategy, licensing, business development and corporate investment, in the UK and US. Notable experience includes roles at UCB Group, Sanofi-Genzyme and AstraZeneca across a diverse range of therapy areas and modalities. Claire serves on the board of a number of Life Science companies, the Enterprise Advisory Board of the University of Liverpool and acts as an advisor for Innovate-UK. Claire received her BSc in Physiology and PhD in Pharmacology in Glasgow. She also holds an MBA focused on entrepreneurship as well as certificates in Investment Management (IMC) and Company Board Direction.

Claire Brown

Partner, Life Sciences

Team

Gaelle joined Oxford Science Enterprises as an Executive Assistant in February 2017. She is experienced in working in administration in Oxford, having been an Administrative Assistant at Oxford Archaeology Limited and previously a Broadcast Assistant at Balliol College. Gaelle is the executive assistant to the life sciences team and coordinates events.

Gaelle Newton

Executive Assistant & Events Co-ordinator

Team

Alex joined Oxford Science Enterprises as Head of Corporate Finance in October 2019. He was previously a medical student at the University of Oxford and a junior doctor in Oxford before joining investment banking in 2007. Over the course of 13 years, he worked on M&A and capital raising across healthcare, as well as energy and infrastructure. He worked at UBS and then Lazard in Europe and the Australia Pacific region. His experience includes both large pharma and medtech clients as well as early stage biotech and digital health, traditional and renewable energy generation and transmission for private and public market clients. Alex co-ordinates all fundraising and exits across the enterprises, manages the Investment Committee process and reports on the Investment Portfolio. He represents Oxford Science Enterprises on the boards of Vaccitech and Macrophox and is an observer on the board of Evox Therapeutics.

Alex Hammacher

Head of Strategic Operations & Corporate Finance

Team

Walter joined Oxford Science Enterprises in December 2017, while completing his MEng (First) in Engineering at the University of Oxford. He is currently researching a DPhil in Artificial Intelligence and Robotics at the Oxford Robotics Institute. He works as an Analyst under the AI & Software and Healthtech principals. His time is spent in technical due diligence, parsing papers and code, and in aiding early stage investments.

Walter Goodwin

Analyst, Software & AI

Team

Rachel joined Oxford Science Enterprises as HR Advisor in April 2022. Rachel’s role involves all aspects of HR, including overseeing recruitment and onboarding, managing leave, benefits and payroll, as well as providing advice and support to the team. She also oversees the implementation of effective HR processes and procedures. Prior to this she was an HR Administrator for Oxford University, responsible for looking after the whole employee life cycle, with a special focus on recruitment, onboarding, off-boarding and immigration. Rachel has more than five years’ experience in human resources and recruitment, including establishing and developing new HR functions, and is an Associate Member of the CIPD.

Rachel Mckee

Human Resources Advisor

Team

Jeanette joined Oxford Science Enterprises as an Office Manager and EA to Jim Wilkinson, CFO, in March 2016. She previously worked as an administrator at various placements through Allen Associates. Prior to this, Jeanette spent many years as the Bursary Secretary at an independent school in Kent. She trained as a legal secretary and was previously an administrator for various pension providers. Jeanette is the executive assistant to Alexis Dormandy and Jim Wilkinson.

Jeanette Lovis

Executive Assistant to Chief Executive Officer & Chief Financial Officer

Team

Sive joined Oxford Science Enterprises as Legal Counsel in June 2020. She was previously an Associate at Marriott Harrison, where she focused on venture capital investments. Sive holds an LLB (Law) from the University of Southampton and LLM (Corporate Law) from UCL. Sive works closely with the investment team on the negotiation and execution of new and follow-on investments. She also assists with general corporate, commercial and IP matters.

Sive Ozer

Legal Counsel

Team

Richard joined the Board of Oxford Science Enterprises in April 2022. Richard is a veteran of GE Capital, serving the company for 34 years before retiring as CEO and Chairman in 2018. At GE Capital, Richard held a number of senior executive roles across the US, Asia & Europe leading global teams to develop and execute financing strategies that were critical to the success of a broad range of multi-billion-dollar world-leading businesses. Since leaving GE Capital, Richard has used his experience and expertise to advise companies which are using cutting-edge and innovative technologies to disrupt the financial services industry. Richard has served as a senior advisor to Warburg Pincus and is currently a non-executive director to three of its portfolio companies: Vodeno Technology, Aion and Singular Bank. Richard holds a Bachelor’s degree in Business, with a minor in Economics from Skidmore College, Saratoga Springs, New York, US.

Richard Laxer

Non-Executive Director

Board

Phil joined Oxford Science Enterprises as a Scientist in Residence in September 2021. He brings over 10 years’ experience in immune-oncology and works with the Life Sciences Team to create and develop new portfolio companies. He joined from MacrophOx, a cell therapy company he co-founded during his post-doctoral research, where he served as Chief Technology Officer (and interim CEO) for 3 years. Phil is passionate about early-stage technologies with transformative potential for patients. Phil has a B.Sc. in Biochemistry from Imperial College London and a D.Phil. in Immunotherapy from the University of Oxford.

Phil Jakeman

Scientist in Residence, Life Sciences

Team

Dee joined Oxford Science Enterprises as an Executive Assistant in March 2022. Dee supports Alexis Zervoglos, Heather Roxborough, Colin Roberts, Liliane Chamas and all the Health Tech Team. Prior to Covid, Dee was PepGen’s first Office Manager and has years of experience supporting C-Suite Executives

Dee Hogg

Executive Assistant, Health Tech

Team

Colin joined Oxford Sciences Enterprises as Venture Director (HealthTech) in November 2021. He began his career in medical imaging, working clinically before joining the core team at Voxar Ltd, a high-growth VC-backed medical imaging software spinout from Edinburgh University in 2001. Following the acquisition by Barco NV, Colin played a key role in establishing a new medical advanced software business unit. After Toshiba Medical Systems Corporation (now Canon Medical Systems) acquired the business unit, Colin led strategic business planning and innovation related to medical imaging software R&D, with a particular focus on machine learning AI in imaging. Several years later, he became part of the senior leadership team as Venture Development Director at BioCity Group, a lead accelerator and venture investor, and at We Are Pioneer Group. In addition, Colin is the author or co-author of five medical imaging and image processing patents. At OxSciences, he works with the HealthTech team to create and scale global businesses based on Oxford University’s world-leading science and technology research.

Colin Roberts

Operating Partner, Health Tech

Team

Liliane joined Oxford Science Enterprises in December 2019 and is a Healthtech Investment Principal. Liliane completed her DPhil in Human Genetics (Canadian Rhodes Scholar, St John’s College 2009) at the Oxford Centre for Diabetes, Endocrinology and Metabolism at the University of Oxford. Since, Liliane has worked across global health diplomacy, innovation policy and genetics research on national and international levels. Liliane previously served as Deputy Head of the UK Foreign Commonwealth Office/NHS joint unit, driving partnerships in medical workforce, digital health and life sciences between the United Kingdom, Latin America, South Africa and South East Asia. Before then, she was a Policy Fellow at the Institute for Global Health Innovation at Imperial College London, advising on adoption of health system innovations in low and middle income countries, with a particular focus on Myanmar. At the World Health Organization, Liliane worked on indigenous and refugee health initiatives in Brazil, Paraguay and the Middle East and coordinated global technical guidance for the use of digital health in diabetes, hypertension and smoking cessation. Liliane is an associate member of the Schmidt Science Fellows Academic Council and established and currently runs the Rhodes Scholarships for Syria, Lebanon, Jordan and Palestine. Liliane focuses on healthcare technology and sits on the joint steering committee for Lab10x.

Liliane Chamas

Principal, Health Tech

Team

Tom joined Oxford Science Enterprises as an Investment Manager in November 2021. Before this, Tom was a Venture Capital Portfolio Manager at Legal & General, investing in health tech. Alongside that role, Tom completed a Business Development secondment in a genomic medicine portfolio company. Prior to working in venture capital, Tom worked in Strategy & Transactions for EY, on both corporate and private equity deals across a broad range of sectors. Tom is a Chartered Accountant and holds a MSc in Economics & Strategy from Imperial College University.

Thomas Capon

Investment Manager

Team

Katya joined Oxford Science Enterprises as Senior Partner for Life Sciences in September 2021 bringing two decades of VC experience from the biotech industry. Katya started her VC career in 2002 with Alta Partners, a healthcare focused USA fund, followed by Capricorn Partners in Belgium. She has been a director of a number of public and private companies in Europe and is the past Vice-Chair of InvestEurope. Katya completed her scientific training with a PhD in Cellular & Molecular Biology from the University of Wisconsin-Madison, followed by a postdoc in Microbiology & Immunology from the Stanford School of Medicine.

Katya Smirnyagina

Senior Partner, Life Sciences

Team

Martin joined Oxford Science Enterprises as a founding Principal in 2015. Prior to this, he ran Gatehouse Capital for almost ten years, a technology corporate finance boutique working with early stage UK technology companies. He began his career in VC as Investment Manager, later Investment Director, at Top Technology Ventures in 1997, where he was part of a team responsible for investments in more than 20 early stage British technology companies, including IP Group, Focus Solutions Group and Arieso. He has also served as NED for King’s Arms Yard VCT since 2011, and as a Director of the HDH Wills 1965 Charitable Trust. He holds a BA in Geography from the University of Oxford and an MBA from Ashridge Management College. Martin serves as NED on the boards of Oxford Flow, Bodle Technologies, MoA Technology and Refeyn.

Martin Fiennes

Principal, Deep Tech

Team

Heather joined Oxford Science Enterprises as Partner for the Health Tech investment team in March 2022. She leads the team to identify new opportunities, drive the creation of new enterprises, and supports the growth and development of existing Health Tech businesses. Heather is a highly experienced venture capitalist, with over 15 years investment and company building experience across a range of sectors, including health tech, consumer healthcare, life sciences, medical devices, and food technology. She joined from Optum Ventures where she was a Partner, responsible for establishing and leading the Global health tech investment fund on behalf of Optum, a leading technology-enabled US health services business, part of UnitedHealth Group. Heather has also held investment roles at J&J Innovation as Senior Director and Tate and Lyle Ventures as Principal. She holds a PhD in Clinical Biochemistry from Queen’s University of Belfast.

Heather Roxborough

Partner, Health Tech

Team

Amy joined Oxford Science Enterprises in March 2021 as an Associate in the HeathTech team. Previously, Amy worked as a business consultant with EY Embryonic in the Global Strategy and Transactions practice, helping clients define strategies to future proof their businesses. Amy also brings perspectives from corporate innovation having developed early-stage ideas in liquid biopsy and biosensors at Merck KGaA. In parallel, Amy worked on several Software and AI grassroot concepts that received recognition from Global leaders including the European Space Agency, European Institute of Innovation and Technology and EY Global Innovation. Amy holds a DPhil in Neuroscience from the University of Oxford. Amy assists the Principals to uncover new opportunities in HealthTech.

Amy Kao

Associate, Health Tech

Team

Théa joined Oxford Science Enterprises in March 2020 as Head of Human Resources. She's also responsible for developing and implementing a People Strategy reflective of Oxford Science Enterprises' aims and values. Théa's focus is on talent acquisition, developing high performing teams and introducing HR policies, processes and systems. Prior to joining, Théa worked as an HR Manager in the civil engineering sector where she was responsible for introducing an HR function. Previously she worked as an HR Business Partner in the not for profit sectors where she was responsible for delivering initiatives on reward, performance and employee relations. Théa has 20 years experience in human resources and recruitment. She holds a Level 6 Diploma in Strategic Personnel Management and PGDip in Human Resource Management and is a Chartered Member of the CIPD.

Théa Herlihy

Head of Human Resources

Team

Samantha joined Oxford Science Enterprises in April 2022 as an Associate in the Tech team. Samantha is on secondment from Tanarra Capital, an Australasian alternative asset manager. At Tanarra Capital, Samantha works across public and private equity as an Investment Associate in Venture Capital and the LTV Fund, which is a private-equity style of investing in Australian and New Zealand public companies. Her roles across these two funds include portfolio management, managing portfolio companies and investment due diligence. Previously, Samantha was an investment banking analyst at a boutique advisory firm, focusing on M&A and corporate financings for technology companies. Prior to this, Samantha interned at Bank of America Merrill Lynch in the investment banking division. She holds a Master of Finance from the University of Melbourne.

Samantha Hauptman

Associate, Tech

Team

Jack joined Oxford Science Enterprises as an Accountant in July 2016. He was previously a Business Service Manager at Pearson Buchholz Limited and has eight years of experience in accounting in companies such as CPM UK. He trained as an accountant for three years in Oxford and holds an ACCA. Jack is responsible for all aspects of internal finance, including financial reporting, tax planning and treasury management.

Jack Strudley

Head of Finance

Team

Charo joined Oxford Science Enterprises in July 2020 as a Project Co-ordinator. Charo has experience in supporting startups as a coordinator of the Oxford University Innovation (OUI) Incubator. Prior to OUI, Charo worked in academic publishing for over 20 years. She led teams delivering training programmes in digital publishing for suppliers across Europe, US and Asia. She was also a business development advisor (VSO-CUSO volunteer) for agriculture micro-enterprises in the Lindl region of Tanzania. Charo is a Lean Six Sigma Green Belt Practitioner. She has a BA in Geography and History and a Postgraduate Certificate in Education from the Universidad Complutense of Madrid. Charo manages the Student Entrepreneurship Programme (StEP) and the Frontier accelerator programme.

Charo Bajo

Project Manager

Team

Alexis joined Oxford Science Enterprises as CIO (Tech) in February 2021 having previously worked with the team as an advisor. His career as an entrepreneur began in 1997 when he co-founded Oxford University spinout Opsys Limited to pioneer OLED display technology, which later merged with CDT and was listed on the Nasdaq in 2004. Since then, he has founded and led technology companies across a number of sectors – deep tech (materials science), AI/machine learning (computer vision), digital health (cardiology) – combined with a career in investment banking. Alexis oversees all investments in Health Tech, Deep Tech, Software & AI and is focused on creating and scaling global businesses based on Oxford University’s world-leading science and technology research.

Alexis Zervoglos

Senior Partner, Tech

Team

Matt joined Oxford Science Enterprises as a founding Principal in 2015 and focuses on software and software-enabled businesses. An engineer and geek at heart, he was previously a Managing Director at Goldman Sachs, most recently in Strategic Investing and, prior to that, Fixed Income where he built novel pricing models, analytics, and workflow tools. He holds an MSc in Information Engineering from the University of Cambridge and was trained and sponsored by the Ministry of Defence Engineering and Science Group. Matt represents Oxford Science Enterprises on the boards of Navenio, Mind Foundry, PQShield, Bibliu, Diffblue, OxfordVR, Ultromics, HEXR and Osler.

Matthew Arnold

Principal, Software & AI

Team

Alexandra joined Oxford Science Enterprises as an Executive Assistant in February 2022. She supports Katya Smirnygina, Senior Partner, Sarah Shackelton, Chief of Talent and Claire Brown, Partner. Alexandra was previously the Senior Case Writer at the Saïd Business School, travelling internationally to recruit C-suite executives to share their experiences of cyber breaches to create a series of teaching case studies. Alexandra holds an MBA from the Saïd Business School.

Alexandra Ellis

Executive Assistant, Life Sciences & Tech

Team

Caroline joined Oxford Science Enterprises as Entrepreneur in Residence in February 2022. As an Entrepreneur in Residence (EIR), Caroline will lead the creation and development of a new Health Tech enterprise. She has more than 25 years’ experience working in commercial, government and charitable organisations and before taking up the role, she was CEO of Health Data Research UK (HDR UK). Under Caroline’s leadership HDR UK became established as the national institute for health data science and played a pivotal role in the UK’s pandemic response. She led the creation of the Health Data Research Hubs, which supported the RECOVERY Trial in identifying Dexamethasone as the first drug to be effective against COVID-19, the PRINCIPLE Trial in identifying Budesonide as the first treatment to shorten recovery time in patients not admitted to hospital, and the vaccine rollout by providing access to real-world evidence of vaccine effectiveness. She also led the development of the Health Data Research Innovation Gateway, which is already transforming the scale and impact of UK health data research. Caroline also worked for The PSC where she was a founding director and prior to that she worked as an Engagement Manager at McKinsey & Company. She holds an MBA from Harvard Business School and MEng from the University of Cambridge.

Caroline Cake

Entrepreneur in Residence, Health Tech

Team

Heather Preston joined the Board of Oxford Science Enterprises in late 2021. She is an experienced biotechnology venture capitalist with over 30 years of healthcare experience as a scientist, physician and management consultant. She is currently a Managing General Partner of Pivotal BioVenture Partners, a San Francisco based venture capital fund focused on investing in innovative therapeutics and therapeutic platforms. Prior to joining Pivotal, she was a Firm Partner and Managing Director at TPG Biotech. Prior to this, Heather spent two years with JP Morgan Partners, was an Entrepreneur-in-Residence with New Enterprise Associates and spent five years at McKinsey & Co., leading the pharmaceutical and medical products consulting practice. Heather has an undergraduate degree in biochemistry form from the University of London and a medical degree from the University of Oxford. She completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital, Harvard.

Heather Preston

Non-Executive Director

Board

Bernard has represented the University on the board of Oxford Science Enterprises since its foundation. He has over 30 years of experience in advising UK and international transactions. He was previously Vice-Chairman of JPMorgan and CEO of Evercore Partners International, where he remains the Chairman. He is a retired member of the Council of the University of Oxford and a member of the University’s Remuneration Committee, Finance Committee, Mathematical, Physical and Life Sciences Division Board and Medical Sciences Division Board. He is Chairman of the Ashmolean Museum Board of Visitors, Chairman of the Royal Commission for the Great Exhibition of 1851, Chairman of Garsington Opera, Chairman of the Advisory Board of the Royal Society, a Director of the ERA Foundation and a member of the Advisory Board of Networked Quantum Information Technologies. He is Deputy Steward of Oxford University, Deputy Lieutenant of Oxfordshire and an Honorary Fellow of St. John’s College. He holds an MA from the University of Oxford and is a Fellow of the Royal Society of Chemistry.

Bernard Taylor

Non-Executive Director

Board

George joined Oxford Science Enterprises as an Associate in the Deep Tech team in December 2021. George was previously a strategy consultant at Mastercard, where he specialised in engagements with start-ups and emerging technologies. George holds a First Class MEng in Engineering Science from the University of Oxford, where he was an academic scholar awarded the Geoffrey Griffith Scholarship for performance in engineering. George assists the Principals to uncover new opportunities in Deep Tech.

George Todd

Associate, Deep Tech

Team

Sam joined Oxford Science Enterprises in November 2019 as an Associate. Sam was previously a Strategy Consultant at Monitor Deloitte, focusing on Artificial Intelligence engagements. Prior to this, Sam interned at Elixirr Consulting and in private equity with Abris Capital Partners in Eastern Europe. Sam holds a BA (First) in Philosophy, Politics and Economics from the University of Oxford, where he was an academic scholar and was awarded the Gladstone Scholarship for outstanding performance in PPE. He is also a Fellow of the Royal Society of Arts, Manufactures and Commerce. Sam assists the Principals to uncover new opportunities in AI and software.

Sam Harman

Senior Associate, Software & AI

Team

Peter joined Oxford Science Enterprises as an advisor in 2017. He has extensive experience in growing successful international pharmaceutical and healthcare businesses. Peter was Founder and CEO of Clinigen Group, the FTSE AIM global pharmaceutical and services company. He is currently the Chairman of Benchmark Holdings plc, Enigma Holdings and Mitre Group. He was previously chairman of Ergomed plc, CEO of Penn Pharmaceutical Services and the Executive Vice President of a number of pharmaceutical companies. He co-created Unilabs Clinical Trials International in 1997, which was successfully sold to Icon in 2000. He holds an Executive MBA in Business Administration and Management from the Kellogg School of Management.

Peter George

Advisor

Team

Lottie joined Oxford Science Enterprises in January 2022 as Office Administrator. Lottie’s background is predominantly in customer service and she has vast experience in administration. Having previously worked for Oxford Science Enterprises' incubator space, Grassroots, Lottie used her administrative and organisational skills to manage customers, as well as facilities of the Centre.

Lottie O'Donovan

Office Administrator

Team

Sarah joined Oxford Science Enterprises as Chief Talent Officer in January 2022. She focuses on expanding our international network, and attracting high performing executive and non-executive leadership to our enterprises to support their continued growth. Sarah brings more than 20 years of experience building the boards and senior leadership teams of innovative, fast growth companies. She joins from Abingworth where she advised VC backed biotech companies as Partner for Marketing and Talent. Sarah commenced her career as a US Government economist and trade negotiator working with the computer and pharmaceutical industries. She moved into executive search, leading search and assessment projects for Life Sciences, PE/VC and technology teams at global and boutique firms. Sarah has a BA in International Relations from Pomona College, California, and an MA in Public Affairs from Princeton University.

Sarah Shackelton

Chief Talent Officer

Team

Nick joined Oxford Science Enterprises in July 2020, bringing a decade of investment and corporate finance experience. He is responsible for managing a number of portfolio companies, supporting their growth and development, and investing fresh capital. As part of his role, he serves as a Director on the boards of Argonaut Therapeutics, BibliU, Circadian Therapeutics, Dark Blue Therapeutics, EnzBond, Iota Sciences, Metaboards and Opsydia, and additionally holds a number of board observer positions. Prior to Oxford Science Enterprises, Nick was an Investment Principal at Valiance, a MedTech-focused venture capital firm. He has also held roles as an investor at Nordic Capital and started his career as an investment banker at Bank of America Merrill Lynch. Nick has a Triple First Class MA (Cantab) in Natural Sciences from the University of Cambridge.

Nick Dixon-Clegg

Head of Independent Investments

Team

Simon Boddie is Chief Financial Officer for Oxford University and joined the Board of Oxford Science Enterprises as a University representative in late 2021. He is also a Non-Executive Director of Learning Technologies Group plc, an AIM listed market leader in the fast growing workplace digital learning and talent management market. Prior to joining Oxford University, he was on the Boards of FTSE 250 businesses for 15 years. From 2016 he was Chief Financial Officer of Coats Group plc, the world’s leading industrial thread manufacturer, and previously Group Finance Director of Electrocomponents plc, the global multi-channel provider of industrial and electronic products and solutions. He was also a Non-Executive Director and Chairman of the Audit Committee of Page Group plc, a listed International professional recruitment company, from 2012 to 2021. Prior to this he worked for Diageo, where he held a variety of senior finance positions, Hill Samuel Bank and Price Waterhouse. Simon is a member of the Institute of Chartered Accountants in England and Wales and has an MA from the University of Cambridge.

Simon Boddie

Non-Executive Director

Board

Daoud joined Oxford Science Enterprises as a Part Qualified Management Accountant in August 2021. He was previously an Area Accountant at Enterprise Rent-A-Car and has 3 years of experience in finance/accounting. He graduated with a 1st class bachelor’s in accounting & finance in 2019 and is currently working through the CIMA qualification. Daoud is responsible for assisting across all aspects of technical and commercial accounting duties, contributing to the ongoing development of the finance function and providing support to the wider business.

Daoud Khan

Accountant

Team

Chris has been on the board of Oxford Science Enterprises since its foundation and became Non-Executive Chairman in February 2020. He has extensive experience in leading and advising global financial institutions. He is currently Chairman of Lonrho, the African conglomerate, and Leonteq. He is also a member of the supervisory board of Swiss Prime Site and a Senior Advisor to Lone Star Europe. Chris started his career in investment banking at Barclays de Zoete Wedd. He was Head of European Equity Capital Markets at Credit Suisse before becoming CEO of Man Investments, the global hedge fund, and member of the Man Group’s main board. He is also a fellow of the Royal Society of Arts.

Chris Chambers

Non-Executive Chairman

Board

Jim joined Oxford Science Enterprises as CFO and Director at the time of founding in 2015 and was interim CEO from November 2019 to December 2020. He has over 30 years of experience in the commercial sector. Prior to his role at Oxford Science Enterprises, Jim was the CFO of a number of listed companies, including Informa Group (where he was a founder director), Sportingbet, Johnson Service Group, and IBC Group. He was also CFO at Lonrho after it was taken private in 2013. He trained as an accountant with Deloitte, where he worked for 8 years. Jim works closely with the investment team on all transactions (fundraises and exits) and also oversees all central operations.

Jim Wilkinson

Chief Financial Officer

Team

Andre joined the board of Oxford Science Enterprises in early 2020. He is an experienced deep tech advisor with a background in investment banking. He was previously Managing Director, Global Head of Equity Trading at Deutsche Bank, where he worked from 1994 to 2016. After leaving investment banking, Andre founded Braavos Partners, an IT and biotech investment firm. He sits on the board of Singapore Biotech and Next Biosciences and was previously on the board of Deep Science Ventures and Genesis Genetics. He sits on the board of portfolio companies Osler, Ultromics and PQShield.

Andre Crawford-Brunt

Non-Executive Director

Board

Alexis joined Oxford Science Enterprises as Chief Executive Officer in October 2020. He brings over 25 years of science, technology, and investment experience. Prior to this, Alexis worked for leading European venture capital firm Atomico, advising portfolio companies across Europe and the US on their growth strategies and scaling. He originally trained as a doctor at Oxford University before embarking on a business career, including notable senior management and board experience at Virgin, Orange, Candover, RED, the AIDS charity founded by Bono, Wattbike, the world’s most advanced indoor bike, and Spoke, the men’s online clothes business. He helped launch Virgin Mobile and Virgin Active as well as helping Orange to become the top mobile operator in the UK. At Oxford Science Enterprises Alexis is building on the momentum and success to date, leading the team to create a world leading science and technology business.

Alexis Dormandy

Chief Executive Officer

Team

Craig joined Oxford Science Enterprises as Operating Partner in the Life Sciences team in February 2022. He supports the growth and development of Oxford Science Enterprises’ Life Science businesses, the identification of new opportunities, and formation of new spinouts. Craig brings over 20 years of drug discovery and development expertise, with vast experience as a research scientist managing initial target selection through to Phase 2 clinical studies. He joined from C4X Discovery where he was Chief Scientific Officer and an Executive Board Member for more than six years, guiding its transition from a technology-based company to a therapeutics business. Craig has also worked at a number of biotechnology companies supporting multiple financing deals, the creation and management of strategic collaborations and licensing deals with Pharma. He has a PhD in Respiratory Medicine from Birmingham University and a first-class Biochemistry degree from the University of Surrey.

Craig Fox

Operating Partner, Life Sciences

Team

Emily joined Oxford Science Enterprises in February 2021 as an Associate. Prior to this, Emily gained experience in sustainable finance developing ESG data products at Arabesque S-Ray, where she was responsible for managing the product pipeline, representing market needs, and leading product launches. Emily previously worked with the Responsible Investment Association (RIA) as a Research Associate, supporting RIA in their publications. She holds an MPhil in Environmental Policy from the University of Cambridge, where she researched the effect of energy policy on cleantech venture capital investment in Canada. Emily works in the Investor Relations, Co-investing, and Communications team.

Emily Matthews

Associate, Investor Relations

Team

Pete joined Oxford Science Enterprises as the Head of Property in July 2019. Prior to this, he was a Partner at Bidwells, a property consultancy with a focus on the science and technology sector. Pete was previously a Director at Jones Lang LaSalle, an international property consultancy, where he advised Deutsche Bank, GSK and Sony. He also worked with corporate clients for BNP Paribas Real Estate. Pete holds a BA in French and Italian from Bristol University and is a Member of the Royal Institution of Chartered Surveyors. Pete is responsible for managing our growing property portfolio and for providing strategic advice to our enterprises.

Pete Wilder

Head of Property

Team

Sally joined Oxford Science Enterprises in February 2021 as an Associate in the Life Sciences team. She was previously an Anderson Cancer Center Postdoctoral Fellow at the Rockefeller University in New York where her research focussed on genetic instability at the very earliest stages of cancer development. Prior to that, she completed a PhD at the Francis Crick Institute in London where she uncovered an important role for polyploid cells in driving cancer evolution. Academic research that Sally has contributed to has been published in leading journals including Nature Genetics, Nature Communications and Cancer Discovery. Sally assists the Principals to uncover new opportunities in Life Sciences.

Sally Dewhurst

Senior Associate, Life Sciences

Team

Lilly joined Oxford Science Enterprises as a founding Principal in 2015 and is now Head of Network. In this role, she is responsible for bringing people and projects together in mutually beneficial ways, to build value across the portfolio. She is interested in the ways that serendipity and structure meet within the Oxford ecosystem. Prior to her current role, she was a Partner at RT Ventures, where she backed and raised money for a number of UK and US technology companies, including Oxford Nanopore, E-Therapeutics (LON:ETX) and 4D Pharma (NASDAQ:LBPS). She started her career working at Mosaic Ventures, the early-stage VC firm, and Lansdowne Partners, the London-based investment fund. Supported by the German Academic Scholarship Foundation, she holds a BA in Philosophy, Politics and Economics from Magdalen College, University of Oxford.

Lilly Bussmann

Head of Network

Team